3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pancreatic Neoplasms
4
Breast Neoplasms
3
Melanoma
2
Colorectal Neoplasms
2
Untreated Resectable Pancreatic Adenocarcinoma
1
Resectable Localized Prostate Cancer
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Liver Neoplasms
1
Klatskin Tumor
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Glioma
1
Gastrointestinal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
Gemcitabine
32
Cisplatin
31
durvalumab
15
pembrolizumab
14
Fluorouracil
13
Oxaliplatin
12
Leucovorin
12
Capecitabine
10
Bevacizumab
8
lenvatinib
7
Nivolumab
7
zanidatamab
4
Trastuzumab
4
S 1 (combination)
4
Paclitaxel
4
Liquid Biopsy
4
Irinotecan
4
Carboplatin
4
Albumin-Bound Paclitaxel
4
tremelimumab
3
tislelizumab
3
irinotecan sucrosofate
3
Injections
3
Folfox protocol
3
130-nm albumin-bound paclitaxel
3
toripalimab
2
pertuzumab
2
niraparib
2
ivosidenib
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Hydroxychloroquine
×
1 year
×
Clear all
No trials found.